Rethinking the Pharmaceutical Commercialization Strategy for Precision Medicine

Precision medicine is advancing rapidly. Bringing transformative therapies to market that can dramatically improve patient outcomes. NTRK therapies show up to a 75% overall response rate in NTRK fusion-positive tumors. They have a duration of response up to 35 months and progression-free survival of 28 months. So why are patients still missing out on these therapies? The problem isn’t the science. The pharmaceutical commercialization strategy must also ensure the right patients can access treatment.

Precision Medicine Needs a New Commercial Playbook

Precision medicine depends on the coordinated efforts of three key stakeholders. Each with their own focus:

1. Biopharma: Drives innovation by developing and launching new therapies.

2. Labs: Advance diagnostic capabilities and efficiency.

3. Physicians: Diagnose and treat patients.

There are three things we must do to realize precision medicine’s potential. We must boost testing, raise biomarker awareness, and connect therapies to eligible patients. This demands coordinated effort & behavioral change. Unfortunately, this is often under-resourced and hard to incentivize. Without early alignment, testing lags - and patients miss out.

A strong pharmaceutical commercialization strategy must bring these stakeholders together early. It must also address the barriers preventing patients from being identified and treated.

Innovation Overload: The Engagement Challenge.

Physicians face a constant influx of new therapies, protocols, and guidelines. This is all while staying focused on patient care. Static, generic education often gets ignored. To truly engage, education must be timely, relevant, and actionable.

This is where the pharmaceutical commercialization strategy needs to change. Teams need to focus on the physicians, labs, and patients who need support most.

The Ideal Precision Commercialization Model.

Launching targeted therapies presents unique challenges, but also unique opportunities.

Imagine a world where you have testing data at your fingertips. You have a clear strategic roadmap and a partner to help you execute your tactics. You know where eligible patients are being treated and who they’re being treated by. You can engage pathologists, labs, and physicians on who, how, and when to test. Better yet, you can provide them with peer-to-peer support to further drive awareness. That’s the goal.

A new pharmaceutical commercialization strategy for precision medicine must:

• Engage all key stakeholders to accelerate test readiness and biomarker awareness before launch.
• Apply a precision lens to commercialization. Focus on both the testing and the treatment.
• Use real-world data (RWD) to identify eligible patients and guide engagement. Tailored, timely, data-driven digital with complementary personal engagement.
• Track the success of tactics across engagement, testing rates, conversion, and adjust accordingly.

A data-driven pharmaceutical commercialization strategy can help find missed patients and act sooner.

Great medicines aren’t reaching their true potential. This isn’t just a commercial imperative, it’s critical for patients. Every missed test is a potential missed patient.